2007 Volume 40 Issue 1 Pages 55-60
Pharmacokinetics of a glycopeptide antibiotic, teicoplanin, was examined in patients undergoing continuous hemodialysis (CHD). During CHD treatment, 400 mg of teicoplanin was intravenously administered twice on the first day. Then 400 mg of teicoplanin on the 2nd and 3rd day, then 100 mg was administered once daily on subsequent days. Prescription for CHD was dialysis solution flow ; 500 mL/hr and blood flow ; 80 mL/min using a APF-06S hemofilter. The average level of teicoplanin an hour after administration was 39.6±18.1 μg/mL, and the average trough levels were 12.5±0.9 μg/mL, 13.2±0.8 μg/mL, 12.2±1.0 μg/mL on the 3rd, 5th, and 7th days, respectively. Curative effects were obtained in 7 of 10 patients, and there were no apparent side effects during the study period. It was suggested that our protocol would be useful for teicoplanin administration to patients undergoing CHD.
